---
title: "PHAT: VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294354810.md"
description: "VOQUEZNA, a novel PCAB therapy, is addressing significant unmet needs in GI disorders, achieving strong commercial uptake and operating profitability in 2026. Clinical trials demonstrated superiority over PPIs, and the company projects continued revenue growth, extended exclusivity, and cash flow positivity in 2027.Original document: Phathom Pharmaceuticals, Inc. [PHAT] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T11:21:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294354810.md)
  - [en](https://longbridge.com/en/news/294354810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294354810.md)
generator: "portal-rs"
---

# PHAT: VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivity

VOQUEZNA, a novel PCAB therapy, is addressing significant unmet needs in GI disorders, achieving strong commercial uptake and operating profitability in 2026. Clinical trials demonstrated superiority over PPIs, and the company projects continued revenue growth, extended exclusivity, and cash flow positivity in 2027.

Original document: Phathom Pharmaceuticals, Inc. \[PHAT\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PHAT.US](https://longbridge.com/en/quote/PHAT.US.md)

## Related News & Research

- [Hikers 'relied too much' on AI and had to be rescued. A ranger says it wasn't the first AI-related mishap he's seen.](https://longbridge.com/en/news/298103029.md)
- [ENGN: Detalimogene voraplasmid nears pivotal data and FDA filing, targeting broad NMIBC adoption](https://longbridge.com/en/news/298341602.md)
- [RedHill Biopharma Pushes for Growth Securing Rights to Ferring's $37M Gastrointestinal Drugs Portfolio](https://longbridge.com/en/news/298338593.md)
- [08:30 ETAyble Health Joins Amazon's Health Benefits Connector to expand Virtual GI Care Access to Millions of Americans](https://longbridge.com/en/news/297914378.md)
- [Global PR Agency, Genius PR, Rebrands to Reflect Growth Across Crypto, AI, and O-1 and EB-1 Visa PR](https://longbridge.com/en/news/297960123.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**